Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.41 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GCK | P35557 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12735967 | 0.90 | FAAH (0.44) | FAAHALDH1A1HTTKMT2ANAMPT | |
| SCHEMBL1533056 | 0.86 | FAAH (0.47) | FAAHALDH1A1HTTKMT2ANAMPT | |
| SCHEMBL12735963 | 0.83 | FAAH (0.44) | FAAHALDH1A1HTTRAB9AKMT2A | |
| SCHEMBL1532824 | 0.82 | FAAH (0.52) | FAAHALDH1A1HTTKMT2ANAMPT | |
| SCHEMBL1532829 | 0.82 | FAAH (0.54) | FAAHALDH1A1HTTMAPTKMT2A | |
| Oxalic Acid SCHEMBL5265472 | 0.81 | FAAH (0.51) | FAAHALDH1A1HTTKMT2ANAMPT | |
| SCHEMBL12420822 | 0.80 | NPC1 (0.54) | FAAHHTTNPC1RAB9AL3MBTL1 | |
| SCHEMBL5264996 | 0.79 | NFE2L2 (0.55) | ALDH1A1TEAD1TEAD3NFE2L2MAPT | |
| SCHEMBL1532715 | 0.78 | FAAH (0.62) | FAAHHTTKMT2A | |
| SCHEMBL29976154 | 0.78 | FAAH (0.62) | FAAHHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1849773-B1 | Piperazine derivatives for the treatment of urinary incontinence and pain | ASTELLAS PHARMA INC (JP) | 2013-10-16 | — | — | EP | claimed |
| EP-2564849-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH PAINS IN URINARY ORGANS | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | claimed |
| US-20130030006-A1 | AGENT FOR PREVENTING OR TREATING DISEASES ACCOMPANIED BY URINARY PAIN | ASTELLAS PHARMA INC. (JP) | 2013-01-31 | — | — | US | claimed |
| US-7919495-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-04-05 | — | — | US | claimed |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FMC CORPORATION (US) | 2008-12-11 | — | — | US | claimed |
| US-12637413-B2 | Fatty acid amide hydrolase (FAAH) cleavable prodrugs of thyromimetics and combination with peripherally restricted FAAH inhibitors | AUTOBAHN THERAPEUTICS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250302775-A1 | METHODS FOR THE TREATMENT OF DEPRESSION | AUTOBAHN THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4583857-A1 | METHODS FOR THE TREATMENT OF DEPRESSION | Autobahn Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20240261414-A1 | FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF BRAIN TARGETING ACTIVES AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS | AUTOBAHN THERAPEUTICS INC (US) | 2024-08-08 | — | — | US | disclosed |
| US-20240254075-A1 | FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF THYROMIMETICS AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS | AUTOBAHN THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| WO-2024054996-A1 | METHODS FOR THE TREATMENT OF DEPRESSION | AUTOBAHN THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-4334283-A1 | FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF BRAIN TARGETING ACTIVES AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS | Autobahn Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20130030006-A1 | AGENT FOR PREVENTING OR TREATING DISEASES ACCOMPANIED BY URINARY PAIN | ASTELLAS PHARMA INC. (JP) | 2013-01-31 | — | — | US | disclosed |
| US-7919495-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7919494-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7915261-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20100009972-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100009971-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FMC CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1849773-A1 | PYRIDYL NON-AROMATIC NITROGENATED HETEROCYCLIC-1-CARBOXYLATE ESTER DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302775-A1 | METHODS FOR THE TREATMENT OF DEPRESSION | TRHR, FAAH, TSHR | FAAH 2/4885ALDH1A1 602/4885HTT 1479/4885 |
| US-12637413-B2 | Fatty acid amide hydrolase (FAAH) cleavable prodrugs of thyromimetics and combination with peripherally restricted FAAH inhibitors | FAAH, FAAH2, CNR2 | FAAH 1/4885ALDH1A1 1053/4885HTT 2725/4885 |
| US-20240254075-A1 | FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF THYROMIMETICS AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS | FAAH, FAAH2, FFAR1 | FAAH 1/4885ALDH1A1 685/4885HTT 2658/4885 |
| US-20240261414-A1 | FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF BRAIN TARGETING ACTIVES AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS | FAAH, FAAH2, FFAR1 | FAAH 1/4885ALDH1A1 2257/4885HTT 995/4885 |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FAAH, FAAH2, APEH | FAAH 1/4885ALDH1A1 113/4885HTT 3696/4885 |
| US-20100009972-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | FAAH, FAAH2, CNR2 | FAAH 1/4885ALDH1A1 133/4885HTT 4610/4885 |
| US-20130030006-A1 | AGENT FOR PREVENTING OR TREATING DISEASES ACCOMPANIED BY URINARY PAIN | FAAH, FAAH2, PTGS1 | FAAH 1/4885ALDH1A1 347/4885HTT 2816/4885 |
| US-20100009971-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | FAAH, FAAH2, CNR1 | FAAH 1/4885ALDH1A1 134/4885HTT 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.